

Review

Host-Targeted Therapeutics against Multidrug Resistant Intracellular *Staphylococcus aureus*

Natalia Bravo-Santano ¹, Volker Behrends ¹ and Michal Letek ^{2,*}

¹ Health Sciences Research Centre, University of Roehampton, London SW15 4JD, UK; nbravosantano@gmail.com (N.B.-S.); Volker.Behrends@roehampton.ac.uk (V.B.)

² Department of Molecular Biology, Area of Microbiology, University of León, 24004 León, Spain

* Correspondence: michal.letek@unileon.es

Received: 29 October 2019; Accepted: 25 November 2019; Published: 28 November 2019



Abstract: *Staphylococcus aureus* is a facultative intracellular pathogen that invades and replicates within many types of human cells. *S. aureus* has shown to rapidly overcome traditional antibiotherapy by developing multidrug resistance. Furthermore, intracellular *S. aureus* is protected from the last-resort antibiotics—vancomycin, daptomycin, and linezolid—as they are unable to achieve plasma concentrations sufficient for intracellular killing. Therefore, there is an urgent need to develop novel anti-infective therapies against *S. aureus* infections. Here, we review the current state of the field and highlight the exploitation of host-directed approaches as a promising strategy going forward.

Keywords: *Staphylococcus aureus*; host-targeted; repurposing drugs; intracellular pathogen

1. Methicillin-Resistant *Staphylococcus aureus* (MRSA) Methicillin-Resistant *Staphylococcus Aureus* as an Example of Antibiotic Resistance

Since antibiotics were discovered and introduced into the market, they have become a standard treatment for bacterial infections. Indeed, antibiotics are often administered as a routine prophylactic measure during medical procedures where bacterial infection may occur (e.g., surgery) [1]. In addition, antibiotics are commonly used in agriculture to prevent bacterial infections and, also, as growth promoters [2]. This increasing exposure to antibiotics has contributed to the emergence of multidrug-resistant bacteria.

In particular, the ability to rapidly acquire antibiotic resistance represents one of the major features of *Staphylococcus aureus*. In 1959, methicillin was introduced to treat *S. aureus* infections caused by penicillin-resistant isolates. Two years later, in 1961, the first methicillin-resistant *S. aureus* isolate was reported in the United Kingdom [3]. Since then, several MRSA clones have been identified over the past decades [4]. In fact, many staphylococcal infections are caused by strains that are resistant to multiple antibiotics, which are associated with higher costs and extended hospitalization periods, as well as higher morbidity and mortality rates [5].

Moreover, although MRSA infections were initially identified as nosocomial infections, the number of MRSA infection cases within healthy community settings has risen in the past two decades, especially in the United States [6–8]. Community-acquired MRSA (CA-MRSA) and hospital-acquired MRSA (HA-MRSA) strains differ in their genotypic and phenotypic characteristics. For instance, CA-MRSA isolates are susceptible to most antimicrobials apart from β -lactam antibiotics and erythromycin, whereas HA-MRSA isolates are resistant to most available antibiotics [9].

2. Intracellular MRSA Is Protected from Common Antibiotic Treatments

The opportunistic and facultative intracellular pathogen *S. aureus* is carried by 30% of the global population [10,11], the anterior nares of the nasal cavity being the most common carriage site [12,13].

During nasal colonization, *S. aureus* is capable of internalizing into human nasal epithelial cells, and the colonization of the anterior nares increases the risk of developing bacteraemia in persistent carriers. Skin and soft tissue infections are another common portal of entry, which may lead to the colonization of the bloodstream, and, consequently, organ dysfunction and sepsis [14]. Intracellular *S. aureus* is also associated with recurrent rhinosinusitis, tonsillitis, and chronic osteomyelitis [11]

Host cell invasion and intracellular survival could be used by *S. aureus* to infect macrophages, spread to secondary points of infection, evade immune recognition, and avoid exposure to last-resort antibiotics [15,16]. Importantly, the serum levels that can be reached without causing toxicity of three last resort antibiotics routinely employed to treat MRSA infection—vancomycin, daptomycin, and linezolid—are not sufficient to achieve intracellular killing and the eradication of this pathogen [15]. As a result, patients are often required to receive long treatments of intravenous vancomycin, which is in stark contrast to the in vitro effective killing of *S. aureus* observed for this antibiotic [17]. Moreover, clinical infection relapse is not uncommon, suggesting that the intracellular survival of these bacteria facilitates their resistance to the immune system and current antibiotherapies [18]. In fact, antibiotic treatment failure occurs in 20% of patients, leading to an estimated 20,000 deaths per year in the United States alone [19], despite the fact that the clinical isolates often show sensitivity to the administered antibiotics [20].

3. Current Clinical Management of *S. aureus* Infections

Treatment of *S. aureus* infections is becoming a real challenge, especially considering the emergence of MRSA strains resistant to last-resort antibiotics (i.e., vancomycin) [21], as well as its protection against current antibiotics once internalized [15].

Clinical management of MRSA infections varies depending on the type of infection, as well as the bacterial strain. Overall, most MRSA infections usually require a prolonged period of antibiotic therapy, and the removal of infected tissue or biomaterial in cases of localized infection or prosthetic joint infections, respectively [22].

The current list of antibiotics available and approved to treat MRSA infections are vancomycin, daptomycin, linezolid, and some other antimicrobials that have been recently developed, including tedizolid, telavancin, oritavancin, dalbavancin, ceftaroline, and ceftobiprole [23]. However, these latter antibiotics are mostly employed to treat skin and soft tissue infections, with vancomycin, daptomycin, and linezolid being the top options for non-topical and/or systemic infections. Nevertheless, these three last-resort antibiotics also present some limitations. For example, daptomycin cannot be used to treat pneumonia [24], whereas linezolid is not suitable for bacteraemia or infective endocarditis treatment [25]. In addition, strains with reduced susceptibility to daptomycin and linezolid, as well as vancomycin-intermediate and vancomycin-resistant *S. aureus* (VISA and VRSA) strains have already been reported [26]. In addition, and as discussed above, effective doses of vancomycin, daptomycin, or linezolid cannot be achieved intracellularly without causing toxicity to the patient [15].

Furthermore, it is becoming clear that the complex interaction between the pathogen and the host immune system is preventing the development of an efficient vaccine. For example, different staphylococcal virulence factors, such as protein A, possess immunosuppressive effects, which compromise the immunological memory of the host [27]. Indeed, it has been recently demonstrated that vaccination against staphylococcal antigens located on the cell surface may even aggravate the infection [28]. Another important issue regarding the development of a *S. aureus* vaccine is the use of experimental animals that are not natural hosts of this pathogen [29]. For instance, although some protection against *S. aureus* can be obtained in mice, the translation of this protective effect into humans has failed repeatedly [27].

Therefore, due to the alarming emergence of antibiotic resistance, the lack of a suitable vaccine against *S. aureus* infections and the intracellular protection from last-resort antibiotics, novel therapeutics capable of targeting intracellular *S. aureus* are urgently needed. A recently explored strategy to tackle this problem is the design of antibodies conjugated with bactericidal antibiotics that are specifically

released within the host cell [15]. However, in this approach, the antibiotics are only active due to the lower pH of the phagosome, suggesting that this antibody–antibiotic complex may not be effective against cytosolic *S. aureus* or replicating bacteria within autophagosomes. In addition, the use of antibiotics targeting cell growth or division of the pathogen is still a major selective pressure towards the emergence of resistant strains.

4. Host-Directed Therapies: A Novel Perspective

A recent study has estimated that the development of a new drug that gets market approval costs almost 3 billion United States dollars [30], and this is a process that takes 10–12 years on average [31]. Taking into account the limited lifetime of antibiotics, the consideration of alternative therapeutic strategies aimed at improving the activity of currently available antibiotics might be the only realistic option to combat the antibiotic crisis in the short, medium, and long term [32,33].

As part of their host-defense evasion mechanism, intracellular pathogens—including *S. aureus*—subvert and exploit a wide range of host factors to support their intracellular survival, targeting multiple pathways to assure their intracellular proliferation [17,34]. Hence, the study of host–pathogen interactions may lead to the identification of potentially novel pathogen-specific drug targets and/or host-directed therapeutics [17,35].

Repurposing commercially available drugs that target host pathways hijacked by intracellular pathogens is a particularly interesting strategy [33]. The main advantage of using repurposed drugs is that they show minimal toxicity to the host cell, and that they have already been approved for other clinical purposes, which would significantly reduce the necessary time to have these drugs in the market [34].

In addition, the use of repurposed host-targeted therapeutics in combination with traditional antibiotherapy may increase the lifetime of currently available antibiotics by preventing intracellular pathogens' escape from antibacterial treatment within host cells. This may shorten the length of the treatment required for chronic infections and it should lower the risk of infection relapse.

Indeed, the research focused on host-directed therapies has already identified many drugs that have shown positive effects against intracellular bacterial pathogens (Table 1). These examples provide proof-of-principle about the potential of this approach to improve the outcome of bacterial infections caused by these pathogens. Such therapies have shown the ability to achieve intracellular killing, and they also possess the benefit of preventing the development of antimicrobial resistance [36,37].

Table 1. List of host-directed drugs able to halt the intracellular infection caused by different pathogens.

| Class | Drug | Mechanism of Action | Pathogen | Reference |
|-----------------------------------|-----------------------------------|--|-----------------------------------|-----------|
| Monoclonal antibody | Adalimumab | Anti-TNF α | <i>Mycobacterium tuberculosis</i> | [38] |
| | Anti-interleukin 1 β | Cytokine neutralisation | <i>Helicobacter pylori</i> | [39] |
| | Antipertussis toxins antibody | Enhancement of immunoglobulins | <i>Bordetella pertussis</i> | [40] |
| | Anti-TNF α | Cytokine neutralisation | <i>Helicobacter pylori</i> | [39] |
| | Bevacizumab | Anti-VEGF | <i>Mycobacterium tuberculosis</i> | [41,42] |
| | Nivolumab | Anti-PD-1 | <i>Mycobacterium tuberculosis</i> | [43,44] |
| Repurposed drug | Siltuximab | Anti-interleukin 6 | <i>Mycobacterium tuberculosis</i> | [45] |
| | Aspirin | NSAID, TNF α levels reduction | <i>Mycobacterium tuberculosis</i> | [46] |
| | Chlorpromazine | Calmodulin antagonist | <i>Staphylococcus aureus</i> | [47] |
| | | | <i>Neorickettsia risticii</i> | [48] |
| | | | <i>Salmonella Typhimurium</i> | [49] |
| | ETB067 | Serine-threonine protein kinase (Akt1) inhibitor | <i>Mycobacterium tuberculosis</i> | [50] |
| | Fingolimod | sphingosine-1-phosphate pathway | <i>Bordetella pertussis</i> | [51] |
| | Glibendamide | Cyclooxygenase inhibition | <i>Streptococcus pneumoniae</i> | [52] |
| | | | <i>Salmonella Typhimurium</i> | [50] |
| | H-89 | Protein kinase A (PKA) inhibitor | <i>Coxiella burnetii</i> | [53] |
| | | | <i>Streptococcus pneumoniae</i> | [54] |
| | Ibuprofen | NSAID, cyclooxygenase inhibition | <i>Mycobacterium tuberculosis</i> | [55,56] |
| <i>Mycobacterium tuberculosis</i> | | | [57] | |
| Imatinib mesylate | BCR-ABL tyrosine kinase inhibitor | <i>Anaplasma phagocytophilum</i> | [58] | |

Table 1. Cont.

| Class | Drug | Mechanism of Action | Pathogen | Reference |
|-----------------|----------------|---|-----------------------------------|-----------|
| | Indometacin | Cyclooxygenase inhibition | <i>Streptococcus pneumoniae</i> | [59] |
| | Metformin | Mitochondrial respiratory chain blocker | <i>Mycobacterium tuberculosis</i> | [60] |
| | Niraparib | PARP inhibitor | <i>Mycobacterium tuberculosis</i> | [61] |
| | Phenylbutyrate | Histone deacetylase inhibitor | <i>Mycobacterium tuberculosis</i> | [62] |
| | | | <i>Listeria monocytogenes</i> | [63] |
| | Pimozide | Calcium channel inhibitor | <i>Bacillus subtilis</i> | [63] |
| | | | <i>Salmonella Typhimurium</i> | [63] |
| | | | <i>Escherichia coli</i> | [63] |
| Repurposed drug | Prednisone | Glucocorticoid receptor antagonist | <i>Streptococcus pneumoniae</i> | [64] |
| | | | <i>Mycobacterium tuberculosis</i> | [65] |
| | Raloxifene | Oestrogen receptor modulator | <i>Pseudomonas aeruginosa</i> | [66] |
| | Statins | HMG-CoA reductase inhibitor | <i>Streptococcus pneumoniae</i> | [67,68] |
| | | | <i>Mycobacterium tuberculosis</i> | [69] |
| | Sulforaphane | Histone deacetylase inhibitor | <i>Neisseria gonorrhoeae</i> | [70] |
| | Thapsigargin | Calcium ATPase inhibitor | <i>Coxiella burnetii</i> | [53] |
| | | | <i>Listeria monocytogenes</i> | [71] |
| | Thioridazine | unknown | <i>Staphylococcus aureus</i> | [47] |
| | | | <i>Mycobacterium tuberculosis</i> | [72] |
| | Verapamil | Calcium channel inhibitor | <i>Mycobacterium tuberculosis</i> | [73,74] |
| | | | <i>Chlamydia pneumoniae</i> | [75] |
| | Vorinostat | Histone deacetylase inhibitor | <i>Mycobacterium tuberculosis</i> | [76] |
| | Zileuton | Leukotriene synthesis inhibitor | <i>Mycobacterium tuberculosis</i> | [77] |
| Vitamin | Vitamin D3 | Activation of antimicrobial defenses | <i>Helicobacter pylori</i> | [78] |

Host-directed approaches require a deep understanding of the host–pathogen interactions. In order to gain novel insights about such interactions, individual or combined strategies that include-omics approaches (genomics, transcriptomics, proteomics, and metabolomics) and computational biology have shown great promise. Certainly, genome-wide screens employing RNA interference (RNAi), microarray analyses, and chemical libraries have already been employed to identify host genes required for bacterial entry and intracellular growth of intracellular pathogens such as MRSA [35].

RNAi approaches allow loss-of-function phenotypic analyses to discover novel host-directed targets. For instance, genome-wide RNA interference assays have been performed in *Drosophila* cells to identify host factors exploited and subverted by two intracellular pathogens: *Chlamydia caviae* and *Listeria monocytogenes*. In *C. caviae* infections, the depletion of human genes *TOMM40* or *TOMM22*, which are involved in protein transport to the mitochondria, resulted in a reduction of intracellular bacteria within mammalian cells [79]. Moreover, 116 host genes were identified to be important during *L. monocytogenes* infection and implicated in entry, phagosomal escape, and intracellular replication [80].

Interestingly, a study that employed a genetic approach combining RNAi and automated microscopy revealed the importance of serine-threonine protein kinases (Akt1) in the intracellular survival of several intracellular pathogens. Akt1 kinase acts as a key regulator of several guanosine triphosphatases (GTPases), which are involved in essential host pathways exploited by intracellular pathogens. For example, *Salmonella Typhimurium* is able to activate host Akt1 to control actin dynamics via p21(Cdkn1a)-activated kinase 4 (PAK4) and, hence, facilitate its intracellular survival [50]. Moreover, we recently screened for novel host targets that are essential for the host cell infection of MRSA by means of functional genomics. More specifically, we employed an unbiased short-hairpin RNA (shRNA) lentiviral library to screen 16,000 human genes during intracellular *S. aureus* infection, identifying several host genes important for intracellular MRSA [81]. In particular, we found that silencing the human gene *TRAM2* resulted in a significant reduction of intracellular MRSA, whereas host cell viability was restored, showing its importance during intracellular infection. *TRAM2* is an interactive partner of the sarco/endoplasmic reticulum Ca^{2+} ATPase (SERCA) [82]. Accordingly, we found that very low doses of thapsigargin (an inhibitor of the SERCA pumps) could be used to stop *S. aureus* intracellular survival in combination with conventional antibiotics [81].

The use of metabolomics also represents an interesting approach to gain a better understanding of the metabolic scenario upon intracellular bacterial infection [83,84]. It has been shown that

several intracellular pathogens trigger host cell metabolism changes to support its intracellular survival [85]. For example, *Legionella pneumophila* induce a Warburg-like effect in the host cell by interacting with mitochondria to favour its own replication [86]. *Shigella flexneri* re-routes host central carbon metabolism to obtain an abundant nutrient-flux through the glycolytic pathway that allows its intracellular survival [87]. Moreover, host cholesterol import is required by intracellular *Mycobacterium tuberculosis* to persist inside both macrophages and mice lungs [88]. On the other hand, a reduction in nutrient uptake as well as nucleotide biosynthesis has been recently observed in human airway epithelial cells infected with *S. aureus* [89].

We recently characterized host cell physiology of MRSA-infected cells using mass spectrometry-based metabolomics [17,90]. We found that *S. aureus* infection leads to starvation-induced autophagy due to a block in central carbon metabolism, which is mediated by the energy sensor AMPK (AMP-activated protein kinase). Consequently, a treatment with the AMPK inhibitor dorsomorphin halted intracellular *S. aureus* in HeLa and Human Umbilical Vein Endothelial Cells (HUVECs) [17]. Accordingly, treatments with autophagy inhibitors protect mice from MRSA pneumonia [91].

Once specific host factors or metabolic pathways required by the intracellular pathogen have been described, blocking these pathways—for example, by using drug inhibitors—may be considered as a novel strategy to control bacterial infections. For example, Akt1 and protein kinase A (PKA) inhibitors have been shown to reduce intracellular load of *M. tuberculosis* and *S. aureus* Typhimurium in infected human macrophages [50]. Moreover, host-directed therapies could also aim to enhance host cellular responses against intracellular pathogens to activate innate and adaptive host immune responses or to modulate disproportionate inflammation. Hence, host-directed therapies also include immunomodulatory agents—including monoclonal antibodies or nutritional products—as well as cellular therapy (Table 1). For example, monoclonal antibodies anti-TNF α and anti-interleukins, which reduce tissue-destructive inflammation by cytokine neutralisation, have shown a bactericidal effect against the intracellular pathogens *M. tuberculosis* and *Helicobacter pylori* [38,39,92]. Further, the nutritional product vitamin D3 is also effective against these two pathogens, and its mechanism of action has been described as an activation and enhancement of host antimicrobial defences [78,93].

In addition, several studies have already shown that existing and approved drugs, which are used for other clinical purposes unrelated to infection biology, can influence the outcome of bacterial infections. The main advantage of finding “repurposed drugs” is that they are already clinically approved, shortening the time to reach the clinic [35,53]. An example of repurposed drug is the histone deacetylase inhibitor sulforaphane, which induces the expression of leukocyte protease inhibitor and β -defensin 2 and, therefore, increases the activity of antibiotics against the multidrug-resistant strain *Neisseria gonorrhoeae* [70]. Similarly, imatinib—an ABL tyrosine kinase inhibitor, commercialized as Gleevec—is under early clinical trials to treat complicated infections caused by *M. tuberculosis* [57,94].

To further identify other host-targeted therapeutics against intracellular MRSA, we recently screened a panel of 133 FDA-approved drugs with known host targets to test whether blocking these targets had an effect on intracellular bacterial survival [34]. Interestingly, we found that ibrutinib, a host kinase inhibitor, significantly increased host cell viability and reduced bacterial survival at clinically relevant concentrations. We also determined the mechanism of action of ibrutinib by mass spectrometry-based phosphoproteomics, finding very promising host targets, such as Ephrin receptor 2 (EPHA2), that could be used to further develop a more specific therapy against intracellular *S. aureus* [34].

In summary, Table 2 compresses the host factors that have been identified as important for intracellular *S. aureus* internalization, survival, and/or replication. It also includes the putative function of each pathway and the potential host-directed drug (if known) to tackle such pathway with the aim to impair intracellular *S. aureus*.

Table 2. Host molecular factors hijacked by *S. aureus* during intracellular infection and potential host-directed drugs against intracellular *S. aureus*.

| Host Factor | Putative Function | Reference | Host-Directed Drug | Type |
|---|--|-----------|-----------------------|------------|
| Adherence and Internalization | | | | |
| $\alpha 5\beta 1$ -integrins | Internalization into non-phagocytic cells | [95] | Volociximab * | Antibody |
| FAK | Internalization into non-phagocytic cells | [96,97] | PF-562271 | Inhibitor |
| Src-mediated cortactin | Internalization into non-phagocytic cells | [96,97] | PP2 | Inhibitor |
| β_1 -integrins | Internalization into mast cells | [98] | R1295 * | Antagonist |
| Annexin 2 | Internalization into epithelial cells | [99] | | |
| (PI3K)-Akt | Internalization into endothelial cells | [100] | Nelfinavir * | Inhibitor |
| $\alpha V\beta 3$ -integrin | Internalization into endothelial cells | [101] | Cilengitide * | Inhibitor |
| ERK | Internalization into osteoblast and Hep-2 cells | [102] | SCH772984 * | Inhibitor |
| ERK1/2/MEK | Penetration into airway epithelial cells | [103] | UO126 | Inhibitor |
| ERK | Invasion to fibroblasts | [104] | PD98059 | Inhibitor |
| Hsp60 | Internalization into epithelial cells | [105] | | |
| Hsc70 | Internalization into 293T cells | [106] | | |
| Desmoglein 1 | Adherence to keratinocytes | [107] | | |
| Scavenger protein gp340 | Internalization into A549 cells | [108] | | |
| EGFR | Penetration into airway epithelial cells | [103] | BPDQ | Inhibitor |
| ROCK | Penetration into airway epithelial cells | [103] | Y-27632 | Inhibitor |
| JNK | Penetration into airway epithelial cells | [103] | SP600125 | Inhibitor |
| p38/MAPK | Penetration into airway epithelial cells | [103] | SB202190 | Inhibitor |
| EPHA2 | Invasion/Internalization into epithelial cells | [34] | Ibrutinib | Inhibitor |
| CDK | Adhesion to human bronchial epithelial cells | [97] | Roscovitine | |
| PKA | Internalization into Thp1 macrophages | [97,109] | H-89 | Inhibitor |
| PKC | Internalization into Thp1 macrophages | [97,109] | Bisindolylmaleimide-I | Inhibitor |
| Intracellular Survival and Proliferation | | | | |
| ADAM10 | Cleavage of adherens junction protein E-cadherin | [110] | GI 254023X | Inhibitor |
| AMPK | Induction of autophagy | [17] | Dorsomorphin | Inhibitor |
| ERK | Induction of autophagy | [17] | SCH772984 * | Inhibitor |
| TRAM2 | Ca ²⁺ pump to promote collagen synthesis | [81] | Thapsigargin | Inhibitor |
| p38/MAPK | Subversion of autophagy | [111] | Skepinone-L * | Inhibitor |
| PAK | Cytoskeleton rearrangements | [97] | FRAX597 * | Inhibitor |
| MYL2 | Cytoskeleton rearrangements | [81] | Blebbistatin * | Inhibitor |
| FAM63B | Intracellular trafficking | [81] | | |
| Actin | Promote bacterial movements within the host cell | [95,112] | Cytochalasin D | Inhibitor |
| Rab5 | Promote bacterial movements within the host cell | [112] | | |
| NWASP | Production of actin-comet tails to facilitate movement | [112] | Wiskostatin | Inhibitor |
| TMEM59 | Activation of selective-autophagy | [113] | | |
| RAPGEF3 | Induction of autophagy | [114] | Salirasib * | Inhibitor |
| RAP2B | Induction of autophagy | [114] | | |
| <i>S. aureus</i>-Induced Host Cell Death | | | | |
| Caspase 2 | <i>S. aureus</i> -induced apoptosis | [115] | Z-VDVAD-FMK | Inhibitor |
| Caspase 9 | <i>S. aureus</i> -induced apoptosis | [116] | Z-LEHD-FMK | Inhibitor |
| NLRP3 | <i>S. aureus</i> -induced pyronecrosis | [117] | MCC950 * | Inhibitor |

*: Drugs that could potentially halt intracellular *S. aureus* by targeting the described host pathway, but their effects have not been yet investigated.

5. Conclusions

Future anti-infective therapies may consist in the combination of conventional antibiotics targeting bacterial survival outside of the host cell with host-directed therapies to efficiently eliminate intracellular pathogens. Therefore, a better understanding of host–*S. aureus* interactions during intracellular infection may lead to novel therapeutic strategies by targeting those host cellular pathways exploited by this versatile pathogen.

Author Contributions: Conceptualization, V.B. and M.L.; writing—original draft preparation, N.B.-S.; writing—review and editing, N.B.-S., V.B., and M.L.; supervision, V.B. and M.L.; project administration, V.B. and M.L.; funding acquisition, V.B. and M.L.

Funding: This work was supported by a Roehampton Vice Chancellor’s Scholarship to N.B.-S. and intramural funding from the University of Roehampton to V.B. and M.L.

Acknowledgments: We thank Jolanta Opacka-Juffry, Cokro Leksmono, and Martha Villegas-Montes for their support at the University of Roehampton during the completion of our research work cited in this manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Agodi, A.; Barchitta, M.; Maugeri, A.; Sodano, L.; Pasquarella, C. Appropriate perioperative antibiotic prophylaxis: Challenges, strategies, and quality indicators. *Epidemiol. Prev.* **2015**, *39*, 27–32.
2. McEwen, S.A.; Collignon, P.J. Antimicrobial Resistance: A One Health Perspective. *Microbiol. Spectr.* **2018**, *6*. [[CrossRef](#)] [[PubMed](#)]
3. Jevons, M.P. “Celbenin”—Resistant Staphylococci. *Br. Med. J.* **1961**, *1*, 124–125. [[CrossRef](#)]
4. Hiramatsu, K.; Cui, L.; Kuroda, M.; Ito, T. The emergence and evolution of methicillin-resistant *Staphylococcus aureus*. *Trends Microbiol.* **2001**, *9*, 486–493. [[CrossRef](#)]
5. Ippolito, G.; Leone, S.; Lauria, F.N.; Nicastrì, E.; Wenzel, R.P. Methicillin-resistant *Staphylococcus aureus*: The superbug. *Int. J. Infect. Dis.* **2010**, *14*, 7–11. [[CrossRef](#)] [[PubMed](#)]
6. Drews, T.D.; Temte, J.L.; Fox, B.C. Community-associated methicillin-resistant *Staphylococcus aureus*: Review of an emerging public health concern. *Wis. Med. J.* **2006**, *105*, 52–57.
7. David, M.Z.; Daum, R.S. Community-associated methicillin-resistant *Staphylococcus aureus*: Epidemiology and clinical consequences of an emerging epidemic. *Clin. Microbiol. Rev.* **2010**, *23*, 616–687. [[CrossRef](#)]
8. Otto, M. Community-associated MRSA: What makes them special? *Int. J. Med. Microbiol.* **2013**, *303*, 324–330. [[CrossRef](#)]
9. Naimi, T.S.; Ledell, K.H.; Como-sabetti, K.; Borchardt, S.M.; Boxrud, D.J.; Johnson, S.K.; Fridkin, S.; Boyle, C.O.; Danila, R.N.; Lynfield, R. Comparison of Community- and Health Care-Associated Methicillin-*Staphylococcus aureus* Infection. *JAMA* **2003**, *290*, 2976–2984. [[CrossRef](#)]
10. Sollid, J.U.E.; Furberg, A.S.; Hanssen, A.M.; Johannessen, M. *Staphylococcus aureus*: Determinants of human carriage. *Infect. Genet. Evol.* **2014**, *21*, 531–541. [[CrossRef](#)]
11. Sakr, A.; Brégeon, F.; Mege, J.-L.; Rolain, J.-M.; Blin, O. *Staphylococcus aureus* nasal colonization: An update on mechanisms, epidemiology, risk factors and subsequent infections. *Front. Microbiol.* **2018**, *9*, 1–15. [[CrossRef](#)] [[PubMed](#)]
12. François, P.; Vaudaux, P.; Foster, T.J.; Lew, D.P. Host-Bacteria Interactions in Foreign Body Infections. *Infect. Control Hosp. Epidemiol.* **1996**, *17*, 514–520. [[CrossRef](#)] [[PubMed](#)]
13. Wertheim, H.F.; Melles, D.C.; Vos, M.C.; van Leeuwen, W.; van Belkum, A.; Verbrugh, H.A.; Nouwen, J.L. The role of nasal carriage in *Staphylococcus aureus* infections. *Lancet Infect. Dis.* **2005**, *5*, 751–762. [[CrossRef](#)]
14. Yoshikawa, T.T.; Strausbaugh, L.J. Methicillin-resistant *Staphylococcus aureus*. In *Infection Management for Geriatrics in Long-Term Care Facilities*, 2nd ed.; CRC Press: Boca Raton, FL, USA, 2006; ISBN 9781420021110.
15. Lehar, S.M.; Pillow, T.; Xu, M.; Staben, L.; Kajihara, K.K.; Vandlen, R.; DePalatis, L.; Raab, H.; Hazenbos, W.L.; Hiroshi Morisaki, J.; et al. Novel antibody–antibiotic conjugate eliminates intracellular *S. aureus*. *Nature* **2015**, *527*, 323–328. [[CrossRef](#)] [[PubMed](#)]
16. Jorch, S.K.; Surewaard, B.G.; Hossain, M.; Peiseler, M.; Deppermann, C.; Deng, J.; Bogoslawski, A.; van der Wal, F.; Omri, A.; Hickey, M.J.; et al. Peritoneal GATA6+ macrophages function as a portal for *Staphylococcus aureus* dissemination. *J. Clin. Investig.* **2019**. [[CrossRef](#)]
17. Bravo-Santano, N.; Ellis, J.K.; Mateos, L.M.; Calle, Y.; Keun, H.C.; Behrends, V.; Letek, M. Intracellular *Staphylococcus aureus* Modulates Host Central Carbon Metabolism To Activate Autophagy. *mSphere* **2018**, *3*, e00374–18. [[CrossRef](#)]
18. Kullar, R.; Davis, S.L.; Levine, D.P.; Rybak, M.J. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant *Staphylococcus aureus* bacteremia: Support for consensus guidelines suggested targets. *Clin. Infect. Dis.* **2011**, *52*, 975–981. [[CrossRef](#)]
19. Kourtis, A.P.; Hatfield, K.; Baggs, J.; Mu, Y.; See, I.; Epton, E.; Nadle, J.; Kainer, M.A.; Dumyati, G.; Petit, S.; et al. Vital signs: Epidemiology and recent trends in methicillin-resistant and in methicillin-susceptible *Staphylococcus aureus* bloodstream infections—United States. *Morb. Mortal. Wkly. Rep.* **2019**, *68*, 214. [[CrossRef](#)]
20. Walraven, C.J.; North, M.S.; Marr-Lyon, L.; Deming, P.; Sakoulas, G.; Mercier, R.C. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant *Staphylococcus aureus* bacteraemia. *J. Antimicrob. Chemother.* **2011**, *66*, 2386–2392. [[CrossRef](#)]
21. Howden, B.P.; Davies, J.K.; Johnson, P.D.R.; Stinear, T.P.; Grayson, M.L. Reduced Vancomycin Susceptibility in *Staphylococcus aureus*, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications. *Clin. Microbiol. Rev.* **2010**, *23*, 99–139. [[CrossRef](#)]

22. Tong, S.Y.C.; Davis, J.S.; Eichenberger, E.; Holland, T.L.; Fowler, V.G. *Staphylococcus aureus* infections: Epidemiology, pathophysiology, clinical manifestations, and management. *Clin. Microbiol. Rev.* **2015**, *28*, 603–661. [[CrossRef](#)] [[PubMed](#)]
23. Boswihi, S.S.; Udo, E.E. Methicillin-resistant *Staphylococcus aureus*: An update on the epidemiology, treatment options and infection control. *Curr. Med. Res. Pract.* **2018**, *8*, 18–24. [[CrossRef](#)]
24. Raja, A.; LaBonte, J.; Lebbos, J.; Kirkpatrick, P. Daptomycin. *Nat. Rev. Drug Discov.* **2003**, *2*, 943. [[CrossRef](#)] [[PubMed](#)]
25. Watkins, R.R.; Lemonovich, T.L.; File, T.M., Jr. An evidence-based review of linezolid for the treatment of methicillin-resistant *Staphylococcus aureus* (MRSA): Place in therapy. *Core Evid.* **2012**, *7*, 131–143. [[CrossRef](#)]
26. Nannini, E.; Murray, B.E.; Arias, C.A. Resistance or decreased susceptibility to glycopeptides, daptomycin, and linezolid in methicillin-resistant *Staphylococcus aureus*. *Curr. Opin. Pharm.* **2010**, *10*, 516–521. [[CrossRef](#)]
27. Kobayashi, S.D.; Deleo, F.R. *Staphylococcus aureus* Protein A Promotes Immune Suppression. *MBio* **2013**, *4*, e00746-13. [[CrossRef](#)]
28. Spaulding, A.R.; Salgado-Pabón, W.; Merriman, J.A.; Stach, C.S.; Ji, Y.; Gillman, A.N.; Peterson, M.L.; Schlievert, P.M. Vaccination against *Staphylococcus aureus* pneumonia. *J. Infect. Dis.* **2014**, *209*, 1955–1962. [[CrossRef](#)]
29. Brown, A.F.; Leech, J.M.; Rogers, T.R.; McLoughlin, R.M. *Staphylococcus aureus* colonization: Modulation of host immune response and impact on human vaccine design. *Front. Immunol.* **2014**, *4*, 507. [[CrossRef](#)]
30. DiMasi, J.A.; Grabowski, H.G.; Hansen, R.W. Innovation in the pharmaceutical industry: New estimates of R&D costs. *J. Health Econ.* **2016**, *47*, 20–33.
31. Sun, W.; Sanderson, P.E.; Zheng, W. Drug combination therapy increases successful drug repositioning. *Drug Discov. Today* **2016**, *21*, 1189–1195. [[CrossRef](#)]
32. Zheng, W.; Sun, W.; Simeonov, A. Drug repurposing screens and synergistic drug-combinations for infectious diseases. *Br. J. Pharm.* **2018**, *175*, 181–191. [[CrossRef](#)] [[PubMed](#)]
33. Chiang, C.Y.; Uzoma, I.; Moore, R.T.; Gilbert, M.; Duplantier, A.J.; Panchal, R.G. Mitigating the impact of antibacterial drug resistance through host-directed therapies: Current progress, outlook, and challenges. *MBio* **2018**, *9*, e1092-17. [[CrossRef](#)] [[PubMed](#)]
34. Bravo-Santano, N.; Stöltzing, H.; Cooper, F.; Bileckaja, N.; Majstorovic, A.; Ihle, N.; Mateos, L.M.; Calle, Y.; Behrends, V.; Letek, M. Host-directed kinase inhibitors act as novel therapies against intracellular *Staphylococcus aureus*. *Sci. Rep.* **2019**, *9*, 4876. [[CrossRef](#)] [[PubMed](#)]
35. Schwegmann, A.; Brombacher, F. Host-directed drug targeting of factors hijacked by pathogens. *Sci. Signal.* **2008**, *1*, re8. [[CrossRef](#)]
36. Zumla, A.; Rao, M.; Wallis, R.S.; Kaufmann, S.H.E.; Rustomjee, R.; Mwaba, P.; Vilaplana, C.; Yeboah-Manu, D.; Chakaya, J.; Ippolito, G.; et al. Host-directed therapies for infectious diseases: Current status, recent progress, and future prospects. *Lancet Infect. Dis.* **2016**, *16*, 47–63. [[CrossRef](#)]
37. Kaufmann, S.H.E.; Dorhoi, A.; Hotchkiss, R.S.; Bartenschlager, R. Host-directed therapies for bacterial and viral infections. *Nat. Rev. Drug Discov.* **2018**, *17*, 35–56. [[CrossRef](#)]
38. Wallis, R.S.; van Vuuren, C.; Potgieter, S. Adalimumab Treatment of Life-Threatening Tuberculosis. *Clin. Infect. Dis.* **2009**, *48*, 1429–1432. [[CrossRef](#)]
39. Wroblewski, L.E.; Peek, R.M.; Wilson, K.T. *Helicobacter pylori* and Gastric Cancer: Factors That Modulate Disease Risk. *Clin. Microbiol. Rev.* **2010**, *23*, 713–739. [[CrossRef](#)]
40. Scanlon, K.M.; Skerry, C.; Carbonetti, N.H. Novel therapies for the treatment of pertussis disease. *Pathog. Dis.* **2015**, *73*, ftt074. [[CrossRef](#)]
41. Datta, M.; Via, L.E.; Kamoun, W.S.; Liu, C.; Chen, W.; Seano, G.; Weiner, D.M.; Schimel, D.; England, K.; Martin, J.D.; et al. Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery. *Proc. Natl. Acad. Sci. USA* **2015**, *112*, 1827–1832. [[CrossRef](#)]
42. Oehlers, S.H.; Cronan, M.R.; Scott, N.R.; Thomas, M.I.; Okuda, K.S.; Walton, E.M.; Beerman, R.W.; Crosier, P.S.; Tobin, D.M. Interception of host angiogenic signalling limits mycobacterial growth. *Nature* **2014**, *517*, 612. [[CrossRef](#)] [[PubMed](#)]
43. Singh, A.; Mohan, A.; Dey, A.B.; Mitra, D.K. Inhibiting the Programmed Death 1 Pathway Rescues *Mycobacterium tuberculosis*-Specific Interferon γ -Producing T Cells From Apoptosis in Patients with Pulmonary Tuberculosis. *J. Infect. Dis.* **2013**, *208*, 603–615. [[CrossRef](#)] [[PubMed](#)]

44. Jurado, J.O.; Alvarez, I.B.; Pasquinelli, V.; Martínez, G.J.; Quiroga, M.F.; Abbate, E.; Musella, R.M.; Chuluyan, H.E.; García, V.E. Programmed Death (PD)-1: PD-Ligand 1/PD-Ligand 2 Pathway Inhibits T Cell Effector Functions during Human Tuberculosis. *J. Immunol.* **2008**, *181*, 116–125. [[CrossRef](#)] [[PubMed](#)]
45. Ravimohan, S.; Tamuhla, N.; Steenhoff, A.P.; Letlhogile, R.; Nfanyana, K.; Bellamy, S.L.; MacGregor, R.R.; Gross, R.; Weissman, D.; Bisson, G.P. Immunological profiling of tuberculosis-associated immune reconstitution inflammatory syndrome and non-immune reconstitution inflammatory syndrome death in HIV-infected adults with pulmonary tuberculosis starting antiretroviral therapy: A prospective obse. *Lancet Infect. Dis.* **2015**, *15*, 429–438. [[CrossRef](#)]
46. Tobin, D.M.; Roca, F.J.; Ray, J.P.; Ko, D.C.; Ramakrishnan, L. An Enzyme That Inactivates the Inflammatory Mediator Leukotriene B4 Restricts Mycobacterial Infection. *PLoS ONE* **2013**, *8*, e67828. [[CrossRef](#)]
47. Martins, M.; Bleiss, W.; Marko, A.; Ordway, D.; Viveiros, M.; Leandro, C.; Pacheco, T.; Molnar, J.; Kristiansen, J.E.; Amaral, L. Clinical concentrations of thioridazine enhance the killing of intracellular methicillin-resistant *Staphylococcus aureus*: An in vivo, ex vivo and electron microscopy study. *In Vivo* **2004**, *18*, 787–794.
48. Rikihisa, Y.; Zhang, Y.; Park, J. Role of Ca²⁺ and calmodulin in ehrlichial infection in macrophages. *Infect. Immun.* **1995**, *63*, 2310–2316.
49. Amaral, L.; Kristiansen, J.E.; Frølund Thomsen, V.; Markovich, B. The effects of chlorpromazine on the outer cell wall of *Salmonella* Typhimurium in ensuring resistance to the drug. *Int. J. Antimicrob. Agents* **2000**, *14*, 225–229. [[CrossRef](#)]
50. Kuijl, C.; Savage, N.D.L.; Marsman, M.; Tuin, A.W.; Janssen, L.; Egan, D.A.; Ketema, M.; van den Nieuwendijk, R.; van den Eeden, S.J.F.; Geluk, A.; et al. Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1. *Nature* **2007**, *450*, 725. [[CrossRef](#)]
51. Skerry, C.; Scanlon, K.; Rosen, H.; Carbonetti, N.H. Sphingosine-1-phosphate Receptor Agonism Reduces *Bordetella pertussis*—Mediated Lung Pathology. *J. Infect. Dis.* **2015**, *211*, 1883–1886. [[CrossRef](#)]
52. Koh, G.C.K.W.; Maude, R.R.; Schreiber, M.F.; Limmathurotsakul, D.; Wiersinga, W.J.; Wuthiekanun, V.; Lee, S.J.; Mahavanakul, W.; Chaowagul, W.; Chierakul, W.; et al. Glyburide Is Anti-inflammatory and Associated with Reduced Mortality in Melioidosis. *Clin. Infect. Dis.* **2011**, *52*, 717–725. [[CrossRef](#)] [[PubMed](#)]
53. Czyz, D.M.; Potluri, L.-P.; Jain-Gupta, N.; Riley, S.P.; Martinez, J.J.; Steck, T.L.; Crosson, S.; Shuman, H.A.; Gabay, J.E. Host-directed antimicrobial drugs with broad-spectrum efficacy against intracellular bacterial pathogens. *MBio* **2014**, *5*, e01534-14. [[CrossRef](#)] [[PubMed](#)]
54. Bernard, G.R.; Wheeler, A.P.; Russell, J.A.; Schein, R.; Summer, W.R.; Steinberg, K.P.; Fulkerson, W.J.; Wright, P.E.; Christman, B.W.; Dupont, W.D.; et al. The Effects of Ibuprofen on the Physiology and Survival of Patients with Sepsis. *N. Engl. J. Med.* **1997**, *336*, 912–918. [[CrossRef](#)] [[PubMed](#)]
55. Vilaplana, C.; Marzo, E.; Tapia, G.; Diaz, J.; Garcia, V.; Cardona, P.-J. Ibuprofen Therapy Resulted in Significantly Decreased Tissue Bacillary Loads and Increased Survival in a New Murine Experimental Model of Active Tuberculosis. *J. Infect. Dis.* **2013**, *208*, 199–202. [[CrossRef](#)]
56. Ivanyi, J.; Zumla, A. Nonsteroidal Antiinflammatory Drugs for Adjunctive Tuberculosis Treatment. *J. Infect. Dis.* **2013**, *208*, 185–188. [[CrossRef](#)]
57. Napier, R.J.; Rafi, W.; Cheruvu, M.; Powell, K.R.; Zaunbrecher, M.A.; Bornmann, W.; Salgame, P.; Shinnick, T.M.; Kalman, D. Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis. *Cell Host Microbe* **2011**, *10*, 475–485. [[CrossRef](#)]
58. Lin, M.; Den Dulk-Ras, A.; Hooykaas, P.J.J.; Rikihisa, Y. *Anaplasma phagocytophilum* AnkA secreted by type IV secretion system is tyrosine phosphorylated by Abl-1 to facilitate infection. *Cell. Microbiol.* **2007**, *9*, 2644–2657. [[CrossRef](#)]
59. Bruce Light, R. Indomethacin and Acetylsalicylic Acid Reduce Intrapulmonary Shunt in Experimental Pneumococcal Pneumonia. *Am. Rev. Respir. Dis.* **1986**, *134*, 520–525.
60. Singhal, A.; Jie, L.; Kumar, P.; Hong, G.S.; Leow, M.K.-S.; Paleja, B.; Tsenova, L.; Kurepina, N.; Chen, J.; Zolezzi, F.; et al. Metformin as adjunct antituberculosis therapy. *Sci. Transl. Med.* **2014**, *6*, 263ra159. [[CrossRef](#)]
61. Pirinen, E.; Cantó, C.; Jo, Y.S.; Morato, L.; Zhang, H.; Menzies, K.J.; Williams, E.G.; Mouchiroud, L.; Moullan, N.; Hagberg, C.; et al. Pharmacological Inhibition of Poly(ADP-Ribose) Polymerases Improves Fitness and Mitochondrial Function in Skeletal Muscle. *Cell Metab.* **2014**, *19*, 1034–1041. [[CrossRef](#)]

62. Coussens, A.K.; Wilkinson, R.J.; Martineau, A.R. Phenylbutyrate Is Bacteriostatic against *Mycobacterium tuberculosis* and Regulates the Macrophage Response to Infection, Synergistically with 25-Hydroxy-Vitamin D₃. *PLoS Pathog.* **2015**, *11*, e1005007. [[CrossRef](#)] [[PubMed](#)]
63. Lieberman, L.A.; Higgins, D.E. A small-molecule screen identifies the antipsychotic drug pimozide as an inhibitor of *Listeria monocytogenes* infection. *Antimicrob. Agents Chemother.* **2009**, *53*, 756–764. [[CrossRef](#)] [[PubMed](#)]
64. Blum, C.A.; Nigro, N.; Briel, M.; Schuetz, P.; Ullmer, E.; Suter-Widmer, I.; Winzeler, B.; Bingisser, R.; Elsaesser, H.; Drozdov, D.; et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: A multicentre, double-blind, randomised, placebo-controlled trial. *Lancet* **2015**, *385*, 1511–1518. [[CrossRef](#)]
65. Critchley, J.A.; Young, F.; Orton, L.; Garner, P. Corticosteroids for prevention of mortality in people with tuberculosis: A systematic review and meta-analysis. *Lancet Infect. Dis.* **2013**, *13*, 223–237. [[CrossRef](#)]
66. Ho Sui, S.J.; Lo, R.; Fernandes, A.R.; Caulfield, M.D.G.; Lerman, J.A.; Xie, L.; Bourne, P.E.; Baillie, D.L.; Brinkman, F.S.L. Raloxifene attenuates *Pseudomonas aeruginosa* pyocyanin production and virulence. *Int. J. Antimicrob. Agents* **2012**, *40*, 246–251. [[CrossRef](#)] [[PubMed](#)]
67. Mortensen, E.M.; Pugh, M.J.; Copeland, L.A.; Restrepo, M.I.; Cornell, J.E.; Anzueto, A.; Pugh, J.A. Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia. *Eur. Respir. J.* **2008**, *31*, 611–617. [[CrossRef](#)]
68. Chalmers, J.D.; Singanayagam, A.; Murray, M.P.; Hill, A.T. Prior Statin Use Is Associated with Improved Outcomes in Community-acquired Pneumonia. *Am. J. Med.* **2008**, *121*, 1002–1007. [[CrossRef](#)]
69. Parihar, S.P.; Guler, R.; Khutlang, R.; Lang, D.M.; Hurdal, R.; Mhlanga, M.M.; Suzuki, H.; Marais, A.D.; Brombacher, F. Statin Therapy Reduces the *Mycobacterium tuberculosis* Burden in Human Macrophages and in Mice by Enhancing Autophagy and Phagosome Maturation. *J. Infect. Dis.* **2014**, *209*, 754–763. [[CrossRef](#)]
70. Yedery, D.R.; Jerse, E.A. Augmentation of Cationic Antimicrobial Peptide Production with Histone Deacetylase Inhibitors as a Novel Epigenetic Therapy for Bacterial Infections. *Antibiotics* **2015**, *4*, 44–61. [[CrossRef](#)]
71. Lieberman, L.A.; Higgins, D.E. Inhibition of *Listeria monocytogenes* infection by neurological drugs. *Int. J. Antimicrob. Agents* **2010**, *35*, 292–296. [[CrossRef](#)]
72. Amaral, L.; Viveiros, M. Why thioridazine in combination with antibiotics cures extensively drug-resistant *Mycobacterium tuberculosis* infections. *Int. J. Antimicrob. Agents* **2012**, *39*, 376–380. [[CrossRef](#)] [[PubMed](#)]
73. Martins, M.; Viveiros, M.; Amaral, L. Inhibitors of Ca²⁺ and K⁺ Transport Enhance Intracellular Killing of *M. tuberculosis* by Non-killing Macrophages. *In Vivo* **2008**, *22*, 69–75. [[PubMed](#)]
74. Gupta, S.; Tyagi, S.; Bishai, W.R. Verapamil increases the bactericidal activity of bedaquiline against *Mycobacterium tuberculosis* in a mouse model. *Antimicrob. Agents Chemother.* **2015**, *59*, 673–676. [[CrossRef](#)] [[PubMed](#)]
75. Salin, O.P.; Pohjala, L.L.; Saikku, P.; Vuorela, H.J.; Leinonen, M.; Vuorela, P.M. Effects of coadministration of natural polyphenols with doxycycline or calcium modulators on acute *Chlamydia pneumoniae* infection in vitro. *J. Antibiot.* **2011**, *64*, 747. [[CrossRef](#)]
76. Rao, M.; Valentini, D.; Zumla, A.; Maeurer, M. Evaluation of the efficacy of valproic acid and suberoylanilide hydroxamic acid (vorinostat) in enhancing the effects of first-line tuberculosis drugs against intracellular *Mycobacterium tuberculosis*. *Int. J. Infect. Dis.* **2018**, *69*, 78–84. [[CrossRef](#)]
77. Mayer-Barber, K.D.; Andrade, B.B.; Oland, S.D.; Amaral, E.P.; Barber, D.L.; Gonzales, J.; Derrick, S.C.; Shi, R.; Kumar, N.P.; Wei, W.; et al. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. *Nature* **2014**, *511*, 99. [[CrossRef](#)]
78. Guo, L.; Chen, W.; Zhu, H.; Chen, Y.; Wan, X.; Yang, N.; Xu, S.; Yu, C.; Chen, L. *Helicobacter pylori* Induces Increased Expression of the Vitamin D Receptor in Immune Responses. *Helicobacter* **2013**, *19*, 37–47. [[CrossRef](#)]
79. Derré, I.; Pypaert, M.; Dautry-Varsat, A.; Agaïsse, H. RNAi Screen in *Drosophila* Cells Reveals the Involvement of the Tom Complex in *Chlamydia* Infection. *PLoS Pathog.* **2007**, *3*, e155. [[CrossRef](#)]
80. Cheng, L.W.; Viala, J.P.M.; Stuurman, N.; Wiedemann, U.; Vale, R.D.; Portnoy, D.A. Use of RNA interference in *Drosophila* S2 cells to identify host pathways controlling compartmentalization of an intracellular pathogen. *Proc. Natl. Acad. Sci. USA* **2005**, *102*, 13646–13651. [[CrossRef](#)]
81. Bravo-Santano, N.; Capilla-Lasheras, P.; Mateos, L.M.; Calle, Y.; Behrends, V.L.M. Identification of novel targets for host-directed therapeutics against intracellular *Staphylococcus aureus*. *Sci. Rep.* **2019**, *9*, 1–12. [[CrossRef](#)]

82. Stefanovic, B.; Stefanovic, L.; Schnabl, B.; Bataller, R.; Brenner, D.A. TRAM2 protein interacts with endoplasmic reticulum Ca^{2+} pump Serca2b and is necessary for collagen type I synthesis. *Mol. Cell. Biol.* **2004**, *24*, 1758–1768. [[CrossRef](#)] [[PubMed](#)]
83. Kint, G.; Fierro, C.; Marchal, K.; Vanderleyden, J.; De Keersmaecker, S.C.J. Integration of ‘omics’ data: Does it lead to new insights into host–microbe interactions? *Future Microbiol.* **2010**, *5*, 313–328. [[CrossRef](#)] [[PubMed](#)]
84. Jean Beltran, P.M.; Federspiel, J.D.; Sheng, X.; Cristea, I.M. Proteomics and integrative omic approaches for understanding host–pathogen interactions and infectious diseases. *Mol. Syst. Biol.* **2017**, *13*. [[CrossRef](#)] [[PubMed](#)]
85. Eisenreich, W.; Heesemann, J.; Rudel, T.; Goebel, W. Metabolic host responses to infection by intracellular bacterial pathogens. *Front. Cell. Infect. Microbiol.* **2013**, *3*, 24. [[CrossRef](#)] [[PubMed](#)]
86. Escoll, P.; Song, O.R.O.-R.; Viana, F.; Steiner, B.; Lagache, T.; Olivo-Marin, J.-C.J.C.; Impens, F.; Brodin, P.; Hilbi, H.; Buchrieser, C. *Legionella pneumophila* Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages. *Cell Host Microbe* **2017**, *22*, 302–316. [[CrossRef](#)] [[PubMed](#)]
87. Kentner, D.; Martano, G.; Callon, M.; Chiquet, P.; Brodmann, M.; Burton, O.; Wahlander, A.; Nanni, P.; Delmotte, N.; Grossmann, J.; et al. *Shigella* reroutes host cell central metabolism to obtain high-flux nutrient supply for vigorous intracellular growth. *Proc. Natl. Acad. Sci. USA* **2014**, *111*, 9929–9934. [[CrossRef](#)]
88. Pandey, A.K.; Sasseti, C.M. Mycobacterial persistence requires the utilization of host cholesterol. *Proc. Natl. Acad. Sci. USA* **2008**, *105*, 4376–4380. [[CrossRef](#)]
89. Gierok, P.; Harms, M.; Methling, K.; Hochgräfe, F.; Lalk, M. *Staphylococcus aureus* infection reduces nutrition uptake and nucleotide biosynthesis in a human airway epithelial cell line. *Metabolites* **2016**, *6*, 41. [[CrossRef](#)]
90. Bravo-Santano, N.; Ellis, J.K.; Calle, Y.; Keun, H.C.; Behrends, V.; Letek, M. Intracellular *Staphylococcus aureus* Elicits the Production of Host Very Long-Chain Saturated Fatty Acids with Antimicrobial Activity. *Metabolites* **2019**, *9*, 148. [[CrossRef](#)]
91. Zhu, Y.; Li, H.; Ding, S.; Wang, Y. Autophagy inhibition promotes phagocytosis of macrophage and protects mice from methicillin-resistant *Staphylococcus aureus* pneumonia. *J. Cell. Biochem.* **2018**, *119*, 4808–4814. [[CrossRef](#)]
92. Rossi, J.-F.; Lu, Z.-Y.; Jourdan, M.; Klein, B. Interleukin-6 as a Therapeutic Target. *Clin. Cancer Res.* **2015**, *21*, 1248–1257. [[CrossRef](#)] [[PubMed](#)]
93. Rahman, S.; Rehn, A.; Rahman, J.; Andersson, J.; Svensson, M.; Brighenti, S. Pulmonary tuberculosis patients with a vitamin D deficiency demonstrate low local expression of the antimicrobial peptide LL-37 but enhanced FoxP3+ regulatory T cells and IgG-secreting cells. *Clin. Immunol.* **2015**, *156*, 85–97. [[CrossRef](#)] [[PubMed](#)]
94. Napier, R.J.; Norris, B.A.; Swimm, A.; Giver, C.R.; Harris, W.A.C.; Laval, J.; Napier, B.A.; Patel, G.; Crump, R.; Peng, Z.; et al. Low Doses of Imatinib Induce Myelopoiesis and Enhance Host Anti-microbial Immunity. *PLoS Pathog.* **2015**, *11*, e1004770. [[CrossRef](#)] [[PubMed](#)]
95. Sinha, B.; François, P.P.; Nüsse, O.; Foti, M.; Hartford, O.M.; Vaudaux, P.; Foster, T.J.; Lew, D.P.; Herrmann, M.; Krause, K.H. Fibronectin-binding protein acts as *Staphylococcus aureus* invasin via fibronectin bridging to integrin $\alpha 5\beta 1$. *Cell. Microbiol.* **1999**, *1*, 101–117. [[CrossRef](#)]
96. Agerer, F.; Lux, S.; Michel, A.; Rohde, M.; Ohlsen, K.; Hauck, C.R. Cellular invasion by *Staphylococcus aureus* reveals a functional link between focal adhesion kinase and cortactin in integrin-mediated internalisation. *J. Cell Sci.* **2005**, *118*, 2189–2200. [[CrossRef](#)]
97. Richter, E.; Harms, M.; Ventz, K.; Nölker, R.; Fraunholz, M.J.; Mostertz, J.; Hochgräfe, F. Quantitative Proteomics Reveals the Dynamics of Protein Phosphorylation in Human Bronchial Epithelial Cells during Internalization, Phagosomal Escape, and Intracellular Replication of *Staphylococcus aureus*. *J. Proteome Res.* **2016**, *15*, 4369–4386. [[CrossRef](#)]
98. Goldmann, O.; Tuchscher, L.; Rohde, M.; Medina, E. α -Hemolysin enhances *Staphylococcus aureus* internalization and survival within mast cells by modulating the expression of $\beta 1$ integrin. *Cell. Microbiol.* **2015**, *18*, 807–819. [[CrossRef](#)]
99. Ashraf, S.; Cheng, J.; Zhao, X. Clumping factor A of *Staphylococcus aureus* interacts with AnnexinA2 on mammary epithelial cells. *Sci. Rep.* **2017**, *7*, 40608. [[CrossRef](#)]
100. Oviedo-Boyso, J.; Cortés-Vieyra, R.; Huante-Mendoza, A.; Yu, H.B.; Valdez-Alarcón, J.J.; Bravo-Patiño, A.; Cajero-Juárez, M.; Finlay, B.B.; Baizabal-Aguirre, V.M. The phosphoinositide-3-kinase-akt signaling pathway is important for *Staphylococcus aureus* internalization by endothelial cells. *Infect. Immun.* **2011**, *79*, 4569–4577. [[CrossRef](#)]

101. McDonnell, C.J.; Garciarena, C.D.; Watkin, R.L.; McHale, T.M.; McLoughlin, A.; Claes, J.; Verhamme, P.; Cummins, P.M.; Kerrigan, S.W. Inhibition of major integrin $\alpha V\beta 3$ reduces *Staphylococcus aureus* attachment to sheared human endothelial cells. *J. Thromb. Haemost.* **2016**, *14*, 2536–2547. [[CrossRef](#)]
102. Ellington, J.K.; Elhofy, A.; Bost, K.L.; Hudson, M.C. Involvement of Mitogen-Activated Protein Kinase Pathways in *Staphylococcus aureus* Invasion of Normal Osteoblasts. *Infect. Immun.* **2001**, *69*, 5235–5242. [[CrossRef](#)]
103. Soong, G.; Martin, F.J.; Chun, J.; Cohen, T.S.; Ahn, D.S.; Prince, A. *Staphylococcus aureus* protein A mediates invasion across airway epithelial cells through activation of RhoA GTPase signaling and proteolytic activity. *J. Biol. Chem.* **2011**, *286*, 35891–35898. [[CrossRef](#)] [[PubMed](#)]
104. Zhao, S.; Gao, Y.; Xia, X.; Che, Y.; Wang, Y.; Liu, H.; Sun, Y.; Ren, W.; Han, W.; Yang, J.; et al. TGF- $\beta 1$ promotes *Staphylococcus aureus* adhesion to and invasion into bovine mammary fibroblasts via the ERK pathway. *Microb. Pathog.* **2017**, *106*, 25–29. [[CrossRef](#)] [[PubMed](#)]
105. Dziewanowska, K.; Carson, A.R.; Patti, J.M.; Deobald, C.F.; Bayles, K.W.; Bohach, G.A. Staphylococcal fibronectin binding protein interacts with heat shock protein 60 and integrins: Role in internalization by epithelial cells. *Infect. Immun.* **2000**, *68*, 6321–6328. [[CrossRef](#)] [[PubMed](#)]
106. Hirschhausen, N.; Schlesier, T.; Schmidt, M.A.; Götz, F.; Peters, G.; Heilmann, C. A novel staphylococcal internalization mechanism involves the major autolysin Atl and heat shock cognate protein Hsc70 as host cell receptor. *Cell. Microbiol.* **2010**, *12*, 1746–1764. [[CrossRef](#)] [[PubMed](#)]
107. Askarian, F.; Ajayi, C.; Hanssen, A.-M.; van Sorge, N.M.; Pettersen, I.; Diep, D.B.; Sollid, J.U.E.; Johannessen, M. The interaction between *Staphylococcus aureus* SdrD and desmoglein 1 is important for adhesion to host cells. *Sci. Rep.* **2016**, *6*, 22134. [[CrossRef](#)]
108. Yang, Y.-H.; Jiang, Y.-L.; Zhang, J.; Wang, L.; Bai, X.-H.; Zhang, S.-J.; Ren, Y.-M.; Li, N.; Zhang, Y.-H.; Zhang, Z.; et al. Structural Insights into SraP-Mediated *Staphylococcus aureus* Adhesion to Host Cells. *PLoS Pathog.* **2014**, *10*, e1004169. [[CrossRef](#)]
109. Miller, M.; Dreisbach, A.; Otto, A.; Becher, D.; Bernhardt, J.; Hecker, M.; Peppelenbosch, M.P.; van Dijl, J.M. Mapping of Interactions between Human Macrophages and *Staphylococcus aureus* Reveals an Involvement of MAP Kinase Signaling in the Host Defense. *J. Proteome Res.* **2011**, *10*, 4018–4032. [[CrossRef](#)]
110. Inoshima, I.; Inoshima, N.; Wilke, G.A.; Powers, M.E.; Frank, K.M.; Wang, Y.; Wardenburg, J.B. A *Staphylococcus aureus* pore-forming toxin subverts the activity of ADAM10 to cause lethal infection in mice. *Nat. Med.* **2011**, *17*, 1310–1314. [[CrossRef](#)]
111. Neumann, Y.; Bruns, S.A.; Rohde, M.; Prajsnar, T.K.; Foster, S.J.; Schmitz, I. Intracellular *Staphylococcus aureus* eludes selective autophagy by activating a host cell kinase. *Autophagy* **2016**, *12*, 2069–2084. [[CrossRef](#)]
112. Schröder, A.; Schröder, B.; Roppenser, B.; Linder, S.; Sinha, B.; Fässler, R.; Aepfelbacher, M. *Staphylococcus aureus* Fibronectin Binding Protein-A Induces Motile Attachment Sites and Complex Actin Remodeling in Living Endothelial Cells. *Mol. Biol. Cell* **2006**, *17*, 5198–5210. [[CrossRef](#)] [[PubMed](#)]
113. Boada-Romero, E.; Letek, M.; Fleischer, A.; Pallauf, K.; Ramón-Barros, C.; Pimentel-Muñoz, F.X. TMEM59 defines a novel ATG16L1-binding motif that promotes local activation of LC3. *EMBO J.* **2013**, *32*, 566–582. [[CrossRef](#)] [[PubMed](#)]
114. Mestre, M.B.; Colombo, M.I. CAMP and EPAC are key players in the regulation of the signal transduction pathway involved in the α -hemolysin autophagic response. *PLoS Pathog.* **2012**, *8*, e1002664. [[CrossRef](#)] [[PubMed](#)]
115. Imre, G.; Heering, J.; Takeda, A.-N.; Husmann, M.; Thiede, B.; zu Heringdorf, D.M.; Green, D.R.; van der Goot, F.G.; Sinha, B.; Dötsch, V.; et al. Caspase-2 is an initiator caspase responsible for pore-forming toxin-mediated apoptosis. *EMBO J.* **2012**, *31*, 2615–2628. [[CrossRef](#)] [[PubMed](#)]
116. Rudel, T.; Kepp, O.; Kozjak-Pavlovic, V. Interactions between bacterial pathogens and mitochondrial cell death pathways. *Nat. Rev. Microbiol.* **2010**, *8*, 693. [[CrossRef](#)] [[PubMed](#)]
117. Muñoz-Planillo, R.; Franchi, L.; Miller, L.S.; Núñez, G. A critical role for hemolysins and bacterial lipoproteins in *Staphylococcus aureus*-induced activation of the Nlrp3 inflammasome. *J. Immunol.* **2009**, *183*, 3942–3948. [[CrossRef](#)] [[PubMed](#)]

